• Booz Allen: Goldman Sachs upgrades to buy from neutral. PT up 16% to $102.
  • CACI international: Goldman Sachs downgrades to neutral from buy
  • CarMax: J.P. Morgan downgrades to neutral from overweight. PT up 18% to $110.
  • Derwent: J.P. Morgan upgrades from neutral to overweight targeting GBp 4200.
  • Great Portland Estates: J.P. Morgan upgrades from neutral to overweight targeting GBp 900.
  • Hammerson: J.P. Morgan downgrades from neutral to underweight targeting GBp 2860.
  • ITM Power: RBC upgrades from sector perform to outperform targeting GBp 500.
  • Integra LifeSciences: Truist Securities downgrades to hold from buy, adjusts price target to $71 from $72.
  • J.B. Hunt transport Services: Deutsche Bank upgrades to buy from hold, adjusts price target to $230 from $210
  • JetBlue: Wolfe Research downgrades to underperform from peerperform. PT down 17% to $10.
  • Land Securities: J.P. Morgan downgrades from overweight to neutral, targeting GBp 900.
  • Mckesson Corporation: Morgan Stanley raises price target to $370 from $292, maintains overweight rating
  • Medtronic: Truist Securities downgrades to hold from buy, adjusts price target to $121 from $124.
  • Moderna: Morgan Stanley adjusts price target to $217 From $205, maintains Equal Weight rating.
  • PepsiCo: Credit Suisse adjusts price target to $163 from $164, maintains neutral rating.
  • Procter & Gamble: Credit Suisse lowers price target for procter & gamble to $140 from $145, maintains neutral rating.
  • Regeneron Pharmaceuticals: Morgan Stanley adjusts price target to $632 from $605, maintains equal weight rating.
  • The Boeing Company: JP Morgan advises its customers to buy the stock. The target price is lowered from USD 270 to USD 235.
  • The Clorox Company: Credit Suisse adjusts price target to $140 from $155, maintains underperform rating
  • Thor Industries: Exane BNP Paribas downgrades to underperform from neutral. PT down 19% to $65.
  • Winnebago Industries: D.A. Davidson & Co initiated coverage with a recommendation of buy. PT up 29% to $70.
  • Zimmer Biomet: Truist Securities downgrades to hold from buy, adjusts price target to $142 from $128.